Clinical trials: B Cell Lymphoma, open to volunteers
Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma, Hairy Cell Leukemia (HCL)
- Trial name
- IMPACT (NCT07759661)
- Where
- Italy
- Volunteers
- 64 people
- Sponsor
- IRCCS San Raffaele
Lymphoma, Large B-Cell, Diffuse
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and…
- Trial name
- NCT06289959
- Testing
- cfDNA
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Diffuse Large B-cell Lymphoma
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
- Trial name
- NCT06594640
- Testing
- Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX)
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Non Hodgkin Lymphoma
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
- Trial name
- NCT06707259
- Testing
- anti-CD19 IL10/IL15 CAR-NK
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
MALT Lymphoma of Stomach
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
We hypothesized that a proportion of patients with localized Helicobacter pylori-negative gastric MALT lymphoma may well respond to frontline Helicobacter pylori eradication therapy (HPE) and remain lymphoma-free for the long…
- Trial name
- GastricMALToma (NCT07144657)
- Testing
- Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT07582159
- Testing
- Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
- Trial name
- NCT07439653
- Testing
- TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- TORL Biotherapeutics, LLC
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
- Trial name
- COURAGE (NCT06914037)
- Testing
- CHT101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology.
- Trial name
- NCT07188077
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT06458439
- Testing
- Epcoritamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
- Trial name
- NCT07260812
- Testing
- KSV01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Acute Leukemia, Myelodysplastic Syndrome
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant
- Trial name
- NCT07573111
- Testing
- QUAIL-100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Laguna Biotherapeutics, Inc.
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Diffuse Large B-cell Lymphoma
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
The goal of this clinical trial is to test CD19-7×19 CAR-T cells combined with Tislelizumab in refractory and relapsed diffuse large B lymphoma.
- Trial name
- NCT05659628
- Testing
- CD19-7×19 CAR-T combined with Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Ningbo No. 1 Hospital
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
- Trial name
- VITALIZE (NCT04920617)
- Testing
- DPX-Survivac, Pembrolizumab, CPA
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia.
- Trial name
- NCT06940960
- Testing
- JY231 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
This study is an observational study on the efficacy and safety of auto-HSCT in adult patients with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia who received TCCA conditioning regimen.
- Conditions
- Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult
- Trial name
- TCCA (NCT06060782)
- Testing
- Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.